[1] [1] SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer［J］. Lancet, 2020, 396(10251): 635-648.

[2] [2] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics2020: GLOBOCAN estimates of incidence and mortality worldwidefor 36 cancers in 185 countries［J］. CA-A Cancer Journalfor Clinicians, 2021, 71(3): 209-249.

[3] [3] KARIMI P, ISLAMI F, ANANDASABAPATHY S, et al. Gastriccancer: descriptive epidemiology, risk factors, screening, andprevention［J］. Cancer Epidemiology Biomarkers & Prevention,2014, 23(5): 700-713.

[4] [4] TSVETKOV P, COY S, PETROVA B, et al. Copper induces celldeath by targeting lipoylated TCA cycle proteins［J］. Science,2022, 375(6586): 1254-1261.

[5] [5] TANG D L, CHEN X, KROEMER G. Cuproptosis: a coppertriggeredmodality of mitochondrial cell death［J］. Cell Research,2022, 32(5): 417-418.

[6] [6] COBINE P A, BRADY D C. Cuproptosis: cellular and molecularmechanisms underlying copper-induced cell death［J］. MolecularCell, 2022, 82(10): 1786-1787.

[7] [7] PERCIVAL S S. Copper and immunity［J］. American Journal ofClinical Nutrition, 1998, 67(5 Suppl): 1064S-1068S.

[8] [8] VOLI F, VALLI E, LERRA L, et al. Intratumoral copper modulatesPD-L1 expression and influences tumor immune evasion［J］.Cancer Research, 2020, 80(19): 4129-4144.

[9] [9] CHEN Y Q, TANG L, HUANG W T, et al. Identification andvalidation of a novel cuproptosis-related signature as a prognosticmodel for lung adenocarcinoma［J］. Frontiers in Endocrinology,2022, 13: 960220.

[10] [10] JIANG Z R, YANG L H, JIN L Z, et al. Identification of novelcuproptosis-related lncRNA signatures to predict the prognosis andimmune microenvironment of breast cancer patients［J］. Frontiersin Oncology, 2022, 12: 988680.

[11] [11] XIA Y, LIU X K, ZHANG L P, et al. A new schiff base coordinatedcopper(II) compound induces apoptosis and inhibits tumorgrowth in gastric cancer［J］. Cancer Cell International, 2019, 19:81.

[12] [12] LIU Y, GUAN X, WANG M L, et al. Disulfiram/Copper inducesantitumor activity against gastric cancer via the ROS/MAPK andNPL4 pathways［J］. Bioengineered, 2022, 13(3): 6579-6589.

[13] [13] KUNG J T Y, COLOGNORI D, LEE J T. Long noncoding RNAs:past, present, and future［J］. Genetics, 2013, 193(3): 651-669.

[14] [14] JIA Y L, TIAN C, WANG H Y, et al. Long non-coding RNANORAD/miR-224-3p/MTDH axis contributes to CDDP resistanceof esophageal squamous cell carcinoma by promoting nuclear accumulationof beta-catenin［J］. Molecular Cancer, 2021, 20(1):162.

[15] [15] DU R Y, BAI Y, LI L. Biological networks in gestational diabetesmellitus: insights into the mechanism of crosstalk between longnon-coding RNA and N-6-methyladenine modification［J］. BMCPregnancy and Childbirth, 2022, 22(1): 384.

[16] [16] XU M, XU X N, PAN B, et al. LncRNA SATB2-AS1 inhibitstumor metastasis and affects the tumor immune cell microenvironmentin colorectal cancer by regulating SATB2［J］. MolecularCancer, 2019, 18(1): 135.

[17] [17] PAN J H, ZHANG X Y, FANG X D, et al. Construction on of aferroptosis-related lncRNA-based model to improve the prognosticevaluation of gastric cancer patients based on bioinformatics［J］.Frontiers in Genetics, 2021, 12:739470.

[18] [18] KOLENDA T, RYS M, GUGLAS K, et al. Quantification of longnon-coding RNAs using qRT-PCR: comparison of different cDNAsynthesis methods and RNA stability［J］. Archives of MedicalScience, 2019, 17(4): 1006-1015.

[19] [19] CHEN D S, MELLMAN I. Elements of cancer immunity and thecancer-immune set point［J］. Nature, 2017, 541(7637): 321-330.

[20] [20] ZHANG B, WU Q, LI B, et al. m(6)A regulator-mediated methylationmodification patterns and tumor microenvironment infiltrationcharacterization in gastric cancer［J］. Molecular Cancer,2020, 19(1): 53.

[21] [21] STEPIEN M, JENAB M, FREISLING H, et al. Pre-diagnosticcopper and zinc biomarkers and colorectal cancer risk in the EuropeanProspective Investigation into Cancer and Nutrition cohort［J］. Carcinogenesis, 2017, 38(7): 699-707.

[22] [22] CAO J, DONG R, JIANG L, et al. LncRNA-MM2 Pidentified as amodulator of macrophage M2 polarization［J］. Cancer ImmunologyResearch, 2019, 7(2): 292-305.

[23] [23] BURR M L, SPARBIER C E, CHAN Y C, et al. CMTM6 maintainsthe expression of PD-L1 and regulates anti-tumour immunity［J］. Nature, 2017, 549(7670): 101-105.

[24] [24] BAAS P, SCHERPEREEL A, NOWAK A K, et al. First-line nivolumabplus ipilimumab in unresectable malignant pleural mesothelioma(CheckMate 743): a multicentre, randomised, open-label,phase 3 trial［J］. Lancet, 2021, 397(10272): 375-386.

[25] [25] CHAN T A, YARCHOAN M, JAFFEE E, et al. Development oftumor mutation burden as an immunotherapy biomarker: utility forthe oncology clinic［J］. Annals of Oncology, 2019, 30(1): 44-56.

[26] [26] JANG B S, HAN W, KIM I A. Tumor mutation burden, immunecheckpoint crosstalk and radiosensitivity in single-cell RNA sequencingdata of breast cancer［J］. Radiotherapy and Oncology,2020, 142: 202-209.

[27] [27] LIU Y Q, CHENG L, HUANG W, et al. Genome instabilityrelatedmiRNAs predict survival, immune landscape, and immunotherapyresponses in gastric cancer［J］. Journal of ImmunologyResearch, 2021, 2021: 2048833.

[28] [28] RIZVI N A, HELLMANN M D, SNYDER A, et al. Mutationallandscape determines sensitivity to PD-1 blockade in non-smallcell lung cancer［J］. Science, 2015, 348(6230): 124-128.

[29] [29] ADRIAENS C, STANDAERT L, BARRA J, et al. p53 inducesformation of NEAT1 lncRNA-containing paraspeckles that modulatereplication stress response and chemosensitivity［J］. NatureMedicine, 2016, 22(8): 861-868.

[30] [30] ZHENG L, CHEN J T, ZHOU Z Y, et al. Knockdown of long noncodingRNA HOXD-AS1 inhibits gastric cancer cell growth viainactivating the JAK2/STAT3 pathway［J］. Tumor Biology, 2017,39(5): 1010428317705335.

[31] [31] ZHANG Y, LI L Y, TU Y, et al. A DCS-related lncRNA signaturepredicts the prognosis and chemotherapeutic response of patientswith gastric cancer［J］. Bioscience Reports, 2022, 42(9): 1-17.